Disease introduction
Parkinson’s disease is a degenerative disorder of the central nervous system that results in the deterioration of the patient’s motor skills, speech and other functions. Some patients may be unable to control their disease effectively with prescribed medication, resulting in unpredictable "on/off" fluctuations.
Treatment of Parkinson’s disease
Apomorphine hydrochloride is used to treat Parkinson’s disease. It is often prescribed to patients who are not responding well to other treatments or who experience frequent “off” periods and less control. The drug acts quickly and reliably, meaning those that need to be active at specific times can continue with their normal activities.
Apomorphine is administered subcutaneously:
- By intermittent injections with a ready-loaded disposable pen
- As a continuous infusion using a syringe driver infusion pump with a pre-filled syringe
Infusion therapy with apomorphine
The patient uses a battery-driven, syringe driver infusion pump to deliver a specified continuous amount of the drug when required, adjusting the amount as needed during the day.
To deliver apomorphine, the patient inserts an infusion set under the skin and connects it to the infusion pump. The patient needs to change the infusion set at least once a day.
The neria™ product range
neria™ infusion sets are approved and used for continuous infusion treatment for Parkinson’s Disease.1
The neria™ product range offers a wide variety of infusion sets with different features to help provide the best possible treatment for patients with Parkinson's Disease.
neria™ infusion sets are infusion devices developed specifically for subcutaneous infusion of medication and are tested (in vitro) for use with apomorphine.1
For a complete overview of our neria™ infusion set range, including specifications, please see the table below. The table is also available as a pdf download.
| Product Specifications | neria™ | neria™ detach | neria™ multi | neria™ soft | neria™ soft 90 | neria™ guard |
|---|---|---|---|---|---|---|
| Cannula | Stainless Steel | Stainless Steel | Stainless Steel | Soft | Soft | Soft |
| Insertion angle | 90 degrees | 90 degrees | 90 degrees | 20-45 degrees | 90 degrees | 90 degrees |
| Disconnection feature | No | Yes | No | Yes at site | Yes at site | Yes at site |
| Needle / Introducer needle guage | G27 or G29 | G27 | G27 | G27 | G27 | G27 |
| Needle lengths | 6, 8, 10 or 12 mm | 6,8 or 10mm | Bi-furcated: 8, 10mm Tri-furcated: 8, 10 or 12mm Quad-furcated: 8, 10, 12mm |
13 or 17mm | 6 or 9 mm | 6 or 9 mm |
| Tubing lengths | 60, 80, 110 cm | 60, 80, 110 cm | Total 90 cm | 30, 60, 80, 110 cm | 30, 60, 110 cm | 12, 30, 60, 80, 110 cm |
| Adhesive | Built-in | Built-in | Built-in | Built-in | Built-in | Built-in |
| Needle safety | - | - | - | - | Yes | Yes |
| Priming volumes | 60 cm @ 0.10 ml 80 cm @ 0.12 ml 110 cm @ 0.15 ml |
60 cm @ 0.10 ml 80 cm @ 0.12 ml 110 cm @ 0.15 ml |
Bi-furcated ~ 0.36 ml Tri-furcated ~ 0.43 ml Quad-furcated ~ 0.51 ml |
30 cm @ 0.06 ml 60 cm @ 0.10 ml 80 cm @ 0.12 ml 110 cm @ 0.15 ml |
30 cm @ 0.06 ml 60 cm @ 0.10 ml 110 cm @ 0.15 ml |
12 cm @ 0.04 ml 60 cm @ 0.10 ml 80 cm @ 0.12 ml 110 cm @ 0.15 ml |
1. Statement - Overview of Drug/Device Compatibility Test for the neria™ Range. 24. February 2020. AP-020446-MM. Data on file. Unomedical A/S.
Resources
Find relevant clinical literature about Parkinson's Disease and continuous subcutaneous infusion management below:
Poster discussing subcutaneous drug delivery and nodule prevention.
Sinclair, M. Bendixen and P. K. Schøndorff, 2018
Regina Katzenschlager, Werner Poewe, Olivier Rascol, Claudia Trenkwalder, Günther Deuschl, K Ray Chaudhuri, Tove Henriksen, Teus van Laar,Kevin Spivey, Senthil Vel, Harry Staines, Andrew Lees
Lancet Neurol 2018; 17: 749–59
Sophie Drapier, Alexandre Eusebio, Bertrand Degos, Marc Ve´rin, Franck Durif, Jean Philippe Azulay, Francois Viallet, Tiphaine Rouaud, Caroline Moreau, Luc Defebvre, Valerie Fraix, Christine Tranchant, Karine Andre, Christine Brefel Courbon, Emmanuel Roze, David Devos
J Neurol 2016; 263(6): 1111-9
Roongroj Bhidayasiri, Pedro J. Garcia Ruiz, Tove Henriksen
Parkinsonism and Related Disorders 33 (2016) S42-S48
Tove Henriksen
Neurodegener Dis Manag. 2014;4(3):271-82
Amy Todd, Cherry-Ann James
British journal of community nursing 2008; 13(10):457-63
LINK ABSTRACT: https://pubmed.ncbi.nlm.nih.gov/19057470/
